Get notified when SNDX files again. Create a free account and we'll email you the moment its next filing is analyzed.

Get filing alerts

Red Flags Detected

  • Convertible Notes Indebtedness (new) — New $250M convertible notes add debt service, potential dilution, and default risk if cash conversion or repurchase obligations cannot be met.
NASDAQ: SNDX Syndax Pharmaceuticals Inc 10-Q

Syndax revenue jumps 91.8% to $72.8M; net loss narrows 31.3% to -$49.4M

Filed August 4, 2026 · Period ending June 30, 2026 · Compared to 10-Q Aug 4, 2025 · ~1 min read

Key Changes

  • high

    Revuforj net revenue surged 91% YoY to $54.7M in Q2 2026, driven by a second FDA approval for R/R AML with NPM1m.

    MD&A: Revuforj verify on EDGAR →
  • high

    Niktimvo net revenue rose 67% YoY to $60.3M; Syndax's collaboration revenue share nearly doubled to $18.1M.

    MD&A: Niktimvo verify on EDGAR →
  • high

    Issued $250M of 2.25% convertible senior notes due 2031, adding $5.7M annual interest and potential dilution of ~10.1M shares.

    Notes: Convertible Notes verify on EDGAR →

1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SAIC 10-Q) is open in full — no account needed.

Partner

Trade SNDX commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

Was this report useful?
View original filing on SEC.gov View full financials on EDGAR ↗

Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify